ENTX Entera Bio Ltd
- Stocks
- Healthcare
- NASDAQ: ENTX
Price (delayed)
$3.04
Market cap
$138.82M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.26
Enterprise value
$120.15M
Relative Growth:
Rel. Growth:
27
Relative Strength:
Rel. Strength:
86
Relative Valuation:
Rel. Valuation:
1
Relative Profitability:
Rel. Profitability:
3
Entera is a leader in the development of orally delivered large molecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due
Highlights
The debt has declined by 39% year-on-year and by 8% since the previous quarter
Entera Bio's revenue has soared by 191% YoY but it has decreased by 26% from the previous quarter
The equity has surged by 102% year-on-year but it has declined by 11% since the previous quarter
Entera Bio's gross profit has plunged by 100% from the previous quarter and by 100% YoY
The net income is down by 24% year-on-year and by 5% since the previous quarter
Key stats
What are the main financial stats of ENTX
Market
Valuations
Earnings
Shares outstanding
45.66M
Market cap
$138.82M
Enterprise value
$120.15M
Price to earnings (P/E)
N/A
Price to book (P/B)
8.01
Price to sales (P/S)
857.73
PEG
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
723.78
Revenue
$166,000
Gross profit
$0
Operating income
-$10.59M
Net income
-$10.6M
EBIT
-$10.59M
EBITDA
-$10.55M
Free cash flow
-$6.7M
Per share
Balance sheet
Liquidity
EPS
-$0.26
EPS diluted
-$0.26
Free cash flow per share
-$0.14
Book value per share
$0.38
Revenue per share
$0
TBVPS
$0.42
Total assets
$19.67M
Total liabilities
$2.41M
Debt
$203,000
Equity
$17.26M
Working capital
$17.47M
Debt to equity
0.01
Current ratio
10.47
Quick ratio
10.23
Net debt/EBITDA
1.77
Margins
Efficiency
Dividend
EBITDA margin
-6,356%
Gross margin
N/A
Net margin
-6,386.7%
Operating margin
-6,378.9%
Return on assets
-72.6%
Return on equity
-82.9%
Return on invested capital
N/A
Return on capital employed
-59.4%
Return on sales
-6,378.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ENTX stock price
How has the Entera Bio stock price performed over time
Intraday
8.57%
1 week
11.36%
1 month
60%
1 year
69.83%
YTD
43.4%
QTD
58.33%
Financial performance
How have Entera Bio's revenue and profit performed over time
Revenue
$166,000
Gross profit
$0
Operating income
-$10.59M
Net income
-$10.6M
Gross margin
N/A
Net margin
-6,386.7%
Entera Bio's revenue has soared by 191% YoY but it has decreased by 26% from the previous quarter
Entera Bio's gross profit has plunged by 100% from the previous quarter and by 100% YoY
ENTX's operating margin has surged by 58% year-on-year but it is down by 41% since the previous quarter
The net margin has surged by 57% year-on-year but it has declined by 41% since the previous quarter
Price vs fundamentals
How does ENTX's price correlate with its fundamentals
Growth
What is Entera Bio's growth rate over time
Valuation
What is Entera Bio stock price valuation
P/E
N/A
P/B
8.01
P/S
857.73
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
723.78
The equity has surged by 102% year-on-year but it has declined by 11% since the previous quarter
ENTX's P/B is 60% above its 5-year quarterly average of 5.0 and 10% above its last 4 quarters average of 7.3
Entera Bio's revenue has soared by 191% YoY but it has decreased by 26% from the previous quarter
The stock's price to sales (P/S) is 89% more than its 5-year quarterly average of 453.1 and 69% more than its last 4 quarters average of 507.6
Efficiency
How efficient is Entera Bio business performance
The return on sales has surged by 57% year-on-year but it has declined by 41% since the previous quarter
ENTX's return on equity is up by 17% year-on-year and by 13% since the previous quarter
Entera Bio's ROA has increased by 14% YoY and by 12% from the previous quarter
Dividends
What is ENTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ENTX.
Financial health
How did Entera Bio financials performed over time
Entera Bio's total assets has soared by 96% YoY but it has decreased by 9% from the previous quarter
ENTX's total liabilities has surged by 60% year-on-year and by 9% since the previous quarter
The debt is 99% smaller than the equity
The equity has surged by 102% year-on-year but it has declined by 11% since the previous quarter
Entera Bio's debt to equity has plunged by 75% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.